{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:23:21Z","timestamp":1788459801962,"version":"build-2803163510"},"reference-count":49,"publisher":"American Chemical Society (ACS)","issue":"24","license":[{"start":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:00Z","timestamp":1604534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_ccby_termsofuse.html"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1KL2TR001444"],"award-info":[{"award-number":["1KL2TR001444"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AI133394"],"award-info":[{"award-number":["R21AI133394"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AI141210"],"award-info":[{"award-number":["R21AI141210"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AI14646"],"award-info":[{"award-number":["R21AI14646"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["104797\/Z\/14\/Z"],"award-info":[{"award-number":["104797\/Z\/14\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1059354"],"award-info":[{"award-number":["APP1059354"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000937","name":"Department of Education, Employment and Workplace Relations, Australian Government","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100000937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001791","name":"Griffith University","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100001791","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001794","name":"University of Queensland","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Following the approval of delamanid and pretomanid as new drugs to treat drug-resistant tuberculosis, there is now a renewed interest in bicyclic nitroimidazole scaffolds as a source of therapeutics against infectious diseases. We recently described a nitroimidazopyrazinone bicyclic subclass with promising antitubercular and antiparasitic activity, prompting additional efforts to generate analogs with improved solubility and enhanced potency. The key pendant aryl substituent was modified by (i) introducing polar functionality to the methylene linker, (ii) replacing the terminal phenyl group with less lipophilic heterocycles, or (iii) generating extended biaryl side chains. Improved antitubercular and antitrypanosomal activity was observed with the biaryl side chains, with most analogs achieved 2- to 175-fold higher activity than the monoaryl parent compounds, with encouraging improvements in solubility when pyridyl groups were incorporated. This study has contributed to understanding the existing structure\u2013activity relationship (SAR) of the nitroimidazopyrazinone scaffold against a panel of disease-causing organisms to support future lead optimization.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.0c01372","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T16:24:20Z","timestamp":1604593460000},"page":"15726-15751","source":"Crossref","is-referenced-by-count":25,"title":["Antitubercular and Antiparasitic 2-Nitroimidazopyrazinones\nwith Improved Potency and Solubility"],"prefix":"10.1021","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4512-2592","authenticated-orcid":true,"given":"Chee Wei","family":"Ang","sequence":"first","affiliation":[{"name":"The University of Queensland , , , ,","place":["St. Lucia, Queensland, Australia, 4072"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lendl","family":"Tan","sequence":"additional","affiliation":[{"name":"The University of Queensland , , , ,","place":["St. Lucia, Queensland, Australia, 4072"]},{"name":"Australian Infectious Diseases Research Centre , , ,","place":["St. Lucia, Queensland, Australia, 4067"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa L.","family":"Sykes","sequence":"additional","affiliation":[{"name":"Griffith University , , , ,","place":["Nathan, Queensland, Australia, 4111"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"AbuGharbiyeh","sequence":"additional","affiliation":[{"name":"University of California, San Diego , , , ,","place":["La Jolla, California, United States, 92093"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9294-3927","authenticated-orcid":true,"given":"Anjan","family":"Debnath","sequence":"additional","affiliation":[{"name":"University of California, San Diego , , , ,","place":["La Jolla, California, United States, 92093"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet C.","family":"Reid","sequence":"additional","affiliation":[{"name":"The University of Queensland , , , ,","place":["St. Lucia, Queensland, Australia, 4072"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas P.","family":"West","sequence":"additional","affiliation":[{"name":"The University of Queensland , , , ,","place":["St. Lucia, Queensland, Australia, 4072"]},{"name":"Australian Infectious Diseases Research Centre , , ,","place":["St. Lucia, Queensland, Australia, 4067"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky M.","family":"Avery","sequence":"additional","affiliation":[{"name":"Griffith University , , , ,","place":["Nathan, Queensland, Australia, 4111"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3147-3460","authenticated-orcid":true,"given":"Matthew A.","family":"Cooper","sequence":"additional","affiliation":[{"name":"The University of Queensland , , , ,","place":["St. Lucia, Queensland, Australia, 4072"]},{"name":"Australian Infectious Diseases Research Centre , , ,","place":["St. Lucia, Queensland, Australia, 4067"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9447-2292","authenticated-orcid":true,"given":"Mark A. T.","family":"Blaskovich","sequence":"additional","affiliation":[{"name":"The University of Queensland , , , ,","place":["St. Lucia, Queensland, Australia, 4072"]},{"name":"Australian Infectious Diseases Research Centre , , ,","place":["St. Lucia, Queensland, Australia, 4067"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2020,11,5]]},"reference":[{"key":"2026090314040102900_cit1","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1128\/CMR.00045-14","article-title":"Emerging and reemerging neglected tropical diseases:\na review of key characteristics, risk factors, and the policy and\ninnovation environment","volume":"27","author":"Mackey","year":"2014","journal-title":"Clin. Microbiol. Rev."},{"key":"2026090314040102900_cit2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1473-3099(05)70086-4","article-title":"Lack of development of new antimicrobial drugs: a potential\nserious threat to public health","volume":"5","author":"Norrby","year":"2005","journal-title":"Lancet Infect.\nDis."},{"key":"2026090314040102900_cit3","doi-asserted-by":"publisher","first-page":"7636","DOI":"10.1021\/acs.jmedchem.7b00143","article-title":"Nitroimidazoles:\nmolecular fireworks that combat a broad spectrum of infectious diseases","volume":"60","author":"Ang","year":"2017","journal-title":"J. Med. Chem."},{"key":"2026090314040102900_cit4","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s40265-014-0241-5","article-title":"Delamanid: first global approval","volume":"74","author":"Ryan","year":"2014","journal-title":"Drugs"},{"key":"2026090314040102900_cit5","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1007\/s40265-019-01207-9","article-title":"Pretomanid:\nfirst approval","volume":"79","author":"Keam","year":"2019","journal-title":"Drugs"},{"key":"2026090314040102900_cit6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030466","article-title":"OPC-67683, a nitro-dihydro-imidazooxazole\nderivative with promising action against tuberculosis in vitro and\nin mice","volume":"3","author":"Matsumoto","year":"2006","journal-title":"PLoS Med."},{"key":"2026090314040102900_cit7","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/35016103","article-title":"A small-molecule\nnitroimidazopyran drug candidate for the treatment of tuberculosis","volume":"405","author":"Stover","year":"2000","journal-title":"Nature"},{"key":"2026090314040102900_cit8","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1126\/science.1164571","article-title":"PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release","volume":"322","author":"Singh","year":"2008","journal-title":"Science"},{"key":"2026090314040102900_cit9","doi-asserted-by":"publisher","first-page":"222","DOI":"10.4103\/0976-500X.136121","article-title":"Delamanid: A new armor in combating drug-resistant\ntuberculosis","volume":"5","author":"Xavier","year":"2014","journal-title":"J. Pharmacol. Pharmacother."},{"key":"2026090314040102900_cit10","unstructured":"FDA approves new drug\nfor treatment-resistant forms of tuberculosis that affects the lungs;"},{"key":"2026090314040102900_cit11","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1016\/j.bmcl.2016.03.103","article-title":"Repurposing strategies for tropical\ndisease drug discovery","volume":"26","author":"Klug","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026090314040102900_cit12","doi-asserted-by":"publisher","first-page":"4699","DOI":"10.1128\/AAC.00722-13","article-title":"The R enantiomer\nof the antitubercular drug PA-824 as a potential oral treatment for\nvisceral leishmaniasis","volume":"57","author":"Patterson","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090314040102900_cit13","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.09744","article-title":"The anti-tubercular drug delamanid\nas a potential oral treatment for visceral leishmaniasis","volume":"5","author":"Patterson","year":"2016","journal-title":"Elife"},{"key":"2026090314040102900_cit14","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1093\/jac\/dku422","article-title":"Nitroimidazo-oxazole\ncompound DNDI-VL-2098: an orally effective preclinical drug candidate\nfor the treatment of visceral leishmaniasis","volume":"70","author":"Gupta","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"2026090314040102900_cit15","unstructured":"Drugs for Neglected Diseases\ninitiative;"},{"key":"2026090314040102900_cit16","doi-asserted-by":"publisher","first-page":"4212","DOI":"10.1021\/acs.jmedchem.7b00034","article-title":"7-Substituted 2-nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: novel antitubercular agents lead to a new\npreclinical candidate for visceral leishmaniasis","volume":"60","author":"Thompson","year":"2017","journal-title":"J. Med. Chem."},{"key":"2026090314040102900_cit17","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1021\/acs.jmedchem.7b01581","article-title":"Development of (6R)-2-nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (DNDI-8219): a new lead\nfor visceral leishmaniasis","volume":"61","author":"Thompson","year":"2018","journal-title":"J. Med. Chem."},{"key":"2026090314040102900_cit18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.bmcl.2017.10.067","article-title":"Assessment of a\npretomanid analogue library for African trypanosomiasis: Hit-to-lead\nstudies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides","volume":"28","author":"Thompson","year":"2018","journal-title":"Bioorg.\nMed. Chem. Lett."},{"key":"2026090314040102900_cit19","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1016\/j.bmcl.2017.03.069","article-title":"6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]thiazoles: facile synthesis and comparative appraisal\nagainst tuberculosis and neglected tropical diseases","volume":"27","author":"Thompson","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026090314040102900_cit20","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2147\/DDDT.S60923","article-title":"Profile of delamanid for the treatment of multidrug-resistant\ntuberculosis","volume":"9","author":"Szumowski","year":"2015","journal-title":"Drug Des., Dev. Ther."},{"key":"2026090314040102900_cit21","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1128\/AAC.03823-14","article-title":"In vitro and in vivo activities of the nitroimidazole\nTBA-354 against Mycobacterium tuberculosis","volume":"59","author":"Upton","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090314040102900_cit22","unstructured":"Lessem, E.\n          \n          The tuberculosis treatment\npipeline: activity; but no answers http:\/\/pipelinereport.org\/2016\/tb-treatment."},{"key":"2026090314040102900_cit23","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1021\/jm501608q","article-title":"Synthesis\nand structure\u2013activity relationships for extended side chain\nanalogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)","volume":"58","author":"Palmer","year":"2015","journal-title":"J. Med. Chem."},{"key":"2026090314040102900_cit24","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1021\/acsmedchemlett.5b00202","article-title":"Synthesis and biological evaluation of polar functionalities\ncontaining nitrodihydroimidazooxazoles as anti-TB agents","volume":"6","author":"Yempalla","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"2026090314040102900_cit25","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1021\/acs.jmedchem.5b01699","article-title":"Repositioning antitubercular\n6-nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for\nneglected tropical diseases: structure\u2013activity studies on\na preclinical candidate for visceral leishmaniasis","volume":"59","author":"Thompson","year":"2016","journal-title":"J. Med. Chem."},{"key":"2026090314040102900_cit26","doi-asserted-by":"publisher","first-page":"11349","DOI":"10.1021\/acs.jmedchem.8b01578","article-title":"Design, synthesis, and biological evaluation of 2-nitroimidazopyrazin-one\/\u2013es\nwith antitubercular and antiparasitic activity","volume":"61","author":"Jarrad","year":"2018","journal-title":"J. Med. Chem."},{"key":"2026090314040102900_cit27","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ejmech.2016.04.064","article-title":"Nitroimidazole carboxamides as antiparasitic\nagents targeting Giardia lamblia, Entamoeba histolytica and Trichomonas vaginalis","volume":"120","author":"Jarrad","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"2026090314040102900_cit28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejmech.2016.08.016","article-title":"Novel multi-target-directed\nligands for Alzheimer\u2019s disease: combining cholinesterase inhibitors\nand 5-HT6 receptor antagonists. Design, synthesis and biological\nevaluation","volume":"124","author":"Wie\u0328ckowska","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"2026090314040102900_cit29","unstructured":"Hasvold, L.; Hexamer, L.; Li, G.; Lin, N.-H.; Sham, H.; Sullivan, G.; Wang, L.; Xia, P.\n          Heterocyclic kinase inhibitors. US20,040,254,159A1, 2004."},{"key":"2026090314040102900_cit30","unstructured":"Albrecht, B. K.; Audia, J. E.; Cook, A. S.; Dakin, L. A.; Duplessis, M.; Gehling, V. S.; Harmange, J.-C.; Nasveschuk, C. G.; Vaswani, R. G.\n          Modulators\nof methyl modifying enzymes, compositions and uses thereof. US9,085,583B2, 2014."},{"key":"2026090314040102900_cit31","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.bmcl.2016.12.081","article-title":"Design, synthesis and biological activity evaluation of novel 2,6-difluorobenzamide\nderivatives through FtsZ inhibition","volume":"27","author":"Bi","year":"2017","journal-title":"Bioorg.\nMed. Chem. Lett."},{"key":"2026090314040102900_cit32","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1021\/jm201184h","article-title":"Identification, design and biological evaluation of\nheterocyclic quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2)","volume":"55","author":"Leung","year":"2012","journal-title":"J. Med. Chem."},{"key":"2026090314040102900_cit33","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1021\/jm2012276","article-title":"Structure\u2013activity\nrelationships for amide-, carbamate-, and urea-linked analogues of\nthe tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)","volume":"55","author":"Blaser","year":"2012","journal-title":"J. Med. Chem."},{"key":"2026090314040102900_cit34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejmech.2016.09.030","article-title":"Pyrazolo[1,5-a]pyridine-3-carboxamide hybrids: design, synthesis and\nevaluation of anti-tubercular activity","volume":"125","author":"Lu","year":"2017","journal-title":"Eur.\nJ. Med. Chem."},{"key":"2026090314040102900_cit35","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ejpb.2016.02.002","article-title":"Effects of gastric pH on oral drug\nabsorption: in vitro assessment using a dissolution\/permeation system\nreflecting the gastric dissolution process","volume":"101","author":"Kataoka","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"2026090314040102900_cit36","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/ja.2015.52","article-title":"Activity of\nlipophilic and hydrophilic drugs against dormant and replicating Mycobacterium tuberculosis","volume":"68","author":"Piccaro","year":"2015","journal-title":"J. Antibiot."},{"key":"2026090314040102900_cit37","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.str.2011.11.001","article-title":"Structure of Ddn, the deazaflavin-dependent\nnitroreductase from Mycobacterium tuberculosis involved\nin bioreductive activation of PA-824","volume":"20","author":"Cellitti","year":"2012","journal-title":"Structure"},{"key":"2026090314040102900_cit38","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1021\/jm901207n","article-title":"Synthesis and structure\u2013activity studies of\nbiphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)","volume":"53","author":"Palmer","year":"2010","journal-title":"J. Med. Chem."},{"key":"2026090314040102900_cit39","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1517\/17460441.2014.960839","article-title":"Novel tactics\nfor designing water-soluble molecules in drug discovery","volume":"9","author":"Walker","year":"2014","journal-title":"Expert Opin. Drug Discovery"},{"key":"2026090314040102900_cit40","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1021\/jm101356p","article-title":"Improvement in aqueous solubility in small molecule\ndrug discovery programs by disruption of molecular planarity and symmetry","volume":"54","author":"Ishikawa","year":"2011","journal-title":"J. Med. Chem."},{"key":"2026090314040102900_cit41","doi-asserted-by":"publisher","first-page":"8238","DOI":"10.1021\/jm5007935","article-title":"Rational use of plasma protein and\ntissue binding data in drug design","volume":"57","author":"Liu","year":"2014","journal-title":"J. Med.\nChem."},{"key":"2026090314040102900_cit42","doi-asserted-by":"publisher","first-page":"6563","DOI":"10.1021\/jm200377r","article-title":"Synthesis and structure-activity relationships of varied\nether linker analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1, 3]oxazine (PA-824)","volume":"54","author":"Thompson","year":"2011","journal-title":"J. Med. Chem."},{"key":"2026090314040102900_cit43","doi-asserted-by":"publisher","first-page":"665","DOI":"10.4269\/ajtmh.2009.09-0015","article-title":"Development of an Alamar BlueTM viability\nassay in 384-well format for high throughput whole cell screening\nof Trypanosoma brucei brucei bloodstream form strain\n427","volume":"81","author":"Sykes","year":"2009","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"2026090314040102900_cit44","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ijpddr.2015.10.001","article-title":"Development and application of a sensitive, phenotypic,\nhigh-throughput image-based assay to identify compound activity against Trypanosoma cruzi amastigotes","volume":"5","author":"Sykes","year":"2015","journal-title":"Int.\nJ. Parasitol."},{"key":"2026090314040102900_cit45","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ejmech.2015.06.019","article-title":"Metronidazole-triazole conjugates: activity against Clostridium difficile and parasites","volume":"101","author":"Jarrad","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"2026090314040102900_cit46","doi-asserted-by":"publisher","first-page":"5421","DOI":"10.1046\/j.1432-1327.2000.01606.x","article-title":"Investigation of the\nAlamar Blue (resazurin) fluorescent dye for the assessment of mammalian\ncell cytotoxicity","volume":"267","author":"O\u2019Brien","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"2026090314040102900_cit47","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1023\/A:1015559603643","article-title":"An improved resazurin-based cytotoxicity\nassay for hepatic cells","volume":"18","author":"McMillian","year":"2002","journal-title":"Cell Biol. Toxicol."},{"key":"2026090314040102900_cit48","doi-asserted-by":"publisher","first-page":"6796","DOI":"10.1039\/C9TB01624D","article-title":"An optimised Cu(0)-RDRP approach\nfor the synthesis of lipidated oligomeric vinyl azlactone: toward\na versatile antimicrobial materials screening platform","volume":"7","author":"Grace","year":"2019","journal-title":"J. Mater. Chem. B"},{"key":"2026090314040102900_cit49","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1021\/acsinfecdis.5b00044","article-title":"Helping chemists\ndiscover new antibiotics","volume":"1","author":"Blaskovich","year":"2015","journal-title":"ACS Infect. Dis."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.0c01372","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/63\/24\/15726\/67316850\/acs.jmedchem.0c01372.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/63\/24\/15726\/67316850\/acs.jmedchem.0c01372.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:04:12Z","timestamp":1788458652000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/63\/24\/15726\/1343684\/Antitubercular-and-Antiparasitic-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,5]]},"references-count":49,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2020,11,5]]},"published-print":{"date-parts":[[2020,12,24]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01372","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,5]]}}}